Positive EBITDA momentum carried forward in Q2
Positive EBITDA momentum carried forward in Q2
Second quarter 2025 (April – June)
- Total revenue amounted to SEK 52.1 (60.9) million, a decrease of SEK 8.8 million corresponding to 14.4%.
- Net sales amounted to SEK 48.2 (57.4) million, a decrease of SEK 9.1 million corresponding to 15.9%. Adjusted for currency effects of SEK -3.8 million, net sales decreased by 9.4%.
- Operating loss amounted to SEK 7.3 (10.8) million.
- EBITDA amounted to SEK 4.4 (1.2) million.
- Net loss for the period amounted to SEK 8.1 (14.3) million.
- Loss per share, before and after dilution, amounted to SEK 0.24 (0.41).
- Cash flow from operating activities amounted to SEK 1.7 (16.8) million corresponding to SEK 0.05 (0.48) per share.
First half-year 2025 (January – June)
- Total revenue amounted to SEK 114.9 (119.7) million, a decrease of SEK 4.8 million corresponding to 4.0%.
- Net sales amounted to SEK 107.3 (111.3) million, a decrease of SEK 4.0 million corresponding to 3.6%. Adjusted for currency effects of SEK -2.0 million, net sales decreased by 1.8%.
- Operating loss amounted to SEK 9.9 (23.7) million.
- EBITDA amounted to SEK 13.8 (-0.3) million.
- Net loss for the period amounted to SEK 12.8 (24.2) million.
- Loss per share, before and after dilution, amounted to SEK 0.37 (0.69).
- Cash flow from operating activities amounted to SEK -10.4 (-2.2) million corresponding to SEK -0.30 (-0.06) per share.
Christine Lind, CEO of Bactiguard comments:
“Bactiguard continued the profitability trend in Q2 with an EBITDA of SEK 4.4 million (Q2 2024: SEK 1.2 million). Revenues amounted to SEK 52.1 million (Q2 2024: SEK 60.9 million), a decrease of 14.4 percent compared to Q2 last year. Total license revenues came in at SEK 34.1 million (Q2 2024: SEK 37.8 million). License partner revenues from BD were SEK 19.2 million (Q2 2024: SEK 27.6 million), lower than previous quarters due to longer than expected timelines to market registration, and from Zimmer Biomet SEK 14.2 million (Q2 2024: SEK 10.2 million) related primarily to minimum royalties. USD currency effects negatively impacted revenues and excluding these, license partner revenues grew by 7.3 percent. The Wound Management portfolio reported revenues of SEK 13.8 million (Q2 2024: SEK 14.7 million). During the quarter early feasibility work related to the cardiology therapeutic area was initiated.”
Bactiguard Holding AB’s (publ) interim report for the second quarter 2025 is available at https://ir.bactiguard.com/
This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, 2025-07-15 at 07:00 CET.
For further information, please contact:
Patrick Bach, CFO +46 761 295 911
Nina Nornholm, Head of Communications & Investor Relations +46 708 550 356
To participate in the audiocast, please use this link: https://ir.bactiguard.com/report/q2-2025/
To participate only by conference call, please register on the link above. Questions can be asked either in writing via the audiocast or orally if you attend the conference call.
For further information, please contact:
Patrick Bach, CFO +46 761 295 911
Nina Nornholm, Head of Communications & Investor Relations +46 708 550 356
To participate in the audiocast, please use this link: https://ir.bactiguard.com/report/q2-2025/
To participate only by conference call, please register on the link above. Questions can be asked either in writing via the audiocast or orally if you attend the conference call.
